Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Background: The effects of the sodium-glucose co-transporter 2 inhibitor empagliflozin on renal and cardiovascular disease have not been tested in a dedicated population of people with chronic kidney disease (CKD). Methods: The EMPA-KIDNEY trial is an international randomized, double-blind, placebo-controlled trial assessing whether empagliflozin 10 mg daily decreases the risk of kidney disease progression or cardiovascular death in people with CKD. People with or without diabetes mellitus (DM) were eligible provided they had an estimated glomerular filtration rate (eGFR) ≥20 but <45 mL/min/1.73 m2 or an eGFR ≥45 but <90 mL/min/1.73 m2 with a urinary albumin:creatinine ratio (uACR) ≥200 mg/g. The trial design is streamlined, as extra work for collaborating sites is kept to a minimum and only essential information is collected. Results: Between 15 May 2019 and 16 April 2021, 6609 people from eight countries in Europe, North America and East Asia were randomized. The mean age at randomization was 63.8 years [standard deviation (SD) 13.9)], 2192 (33%) were female and 3570 (54%) had no prior history of DM. The mean eGFR was 37.5 mL/min/1.73 m2 (SD 14.8), including 5185 (78%) with an eGFR <45 mL/min/1.73 m2. The median uACR was 412 mg/g) (quartile 1–quartile 3 94–1190), with a uACR <300 mg/g in 3194 (48%). The causes of kidney disease included diabetic kidney disease [n = 2057 (31%)], glomerular disease [n = 1669 (25%)], hypertensive/renovascular disease [n = 1445 (22%)], other [n = 808 (12%)] and unknown causes [n = 630 (10%)]. Conclusions: EMPA-KIDNEY will evaluate the efficacy and safety of empagliflozin in a widely generalizable population of people with CKD at risk of kidney disease progression. Results are anticipated in 2022.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Since 2021, two placebo-controlled SGLT2 inhibitor trials (EMPA-KIDNEY and DELIVER) have studied a large number of people without diabetes.”
From Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials (2022) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“EMPA-KIDNEY recruited 6609 patients with chronic kidney disease including 3569 patients without diabetes”
From Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials (2022) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Follow-up was planned until at least 1070 participants had experienced a first primary outcome, in order to provide 90% power at two-sided P=0.05 to detect an 18% relative reduction in risk.14”
From Empagliflozin in Patients with Chronic Kidney Disease (2023) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603 · cited 1×
“All trial eGFR values are estimated using the Chronic Kidney Disease Epidemiology Collaboration creatinine formula available at the start of recruitment (i.e. adjustment for race was included) [39].”
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationAhmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382 · cited 1×
“Since then, several other large placebo-controlled cardiovascular outcome trials with other SGLT-2 inhibitors have reported analogous findings [14, 16, 17].”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 9×
“A total of 6708 participants attended a randomization visit, of which 6609 were randomized (Supplementary data, Table S3b and Figure 3). characteristics of the CREDENCE and DAPA-CKD trials [18, 23–25].”
InfluentialSelf-citation
Research works printed but not linked: 1
- United States Renal Data System 2014 Annual Data Report: Atlas of End-stage Renal Disease in the United States 2014 Bethesda, MD National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
Cited by
Items 101–119 of 119
der Beek, A. B. V. D. A. (2023) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.637600695
Sadovskaya, D. S., Vishnevskii, K. A., Konakova, I. N., Golubeva, O. R., & Бакулина, Н. В. (2023) · HERALD of North-Western State Medical University named after I I Mechnikov · doi:10.17816/mechnikov119586
How to Use Type 2 Diabetes Treatments in Clinical Practice
Karagiannis, T., Liakos, A., & Τσάπας, Α. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch37
Ambrus, C., & Benczúr, B. (2024) · Lege Artis Medicinae · doi:10.33616/lam.34.0025
Madagam, S. (2024) · Urinary and Renal Research · doi:10.54517/urr.v5i1.2402
IgA Nephropathy – Current and Future Perspectives in Treatment
Graňák, K., Vnučák, M., Beliančinová, M., Patricia, K., Blichová, T., Pytliaková, M., & Dedinská, I. (2024) · Acta Medica Martiniana · doi:10.2478/acm-2024-0011
Hypertension in Acute Kidney Injury
Vellanki, K., & Griffin, K. A. (2025) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-81292-7_2
Pleiotropic Effects of Renal Disease Management: Role of SGLT2 Inhibitors
Calderón-Lojero, I. O., Valdez-Ortiz, R., & Sanchez-Pozos, K. A. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815305692125010018
Evolution of Views on Pathogenesis and Treatment of Immunoglobulin A-Nephropathy: What’s New Today?
Николаевна, С. О., Ефремова, Е. В., Богданова, А. Р., & Хасанова, М. И. (2025) · The Russian Archives of Internal Medicine · doi:10.20514/2226-6704-2025-15-5-325-335
Bramlage, P., Lanzinger, S., Mühldorfer, S., Milek, K., Gillessen, A., Veith, R., Ohde, T., Danne, T., Holl, R. W., & Seufert, J. (2023) · Figshare · doi:10.6084/m9.figshare.22790519
Immunoglobulin A nephropathy and disease complications : register-based studies
Jarrick, S. (2023) · DiVA (Digitala Vetenskapliga Arkivet)
SGLT2 Inhibitors for Non-Diabetic Patients With Chronic Kidney Disease: A Literature Review
Mohrag, M. (2025) · University of Bisha Journal for Basic and Applied Sciences · doi:10.65073/3122-3508.1015
Herrington, W. G., & Haynes, R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00025-2
Self-citationRoy, S., Basu, M., Mukhopadhyay, P., & Ghosh, S. K. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1337
Nicola, L. D., Reboldi, G., Fioretto, P., Pontremoli, R., Uster, A., Costanzo, A., & Vassallo, C. (2026) · Journal of Nephrology · doi:10.1093/joneph/aajag019
Self-citationRandomized clinical trials: role of the research nurse
Provenzano, M., Profiti, R., Gandía, L., Fimognari, F. L., Veltri, P., Pezzi, G., Arena, R., Giménez-Civera, E., Forquet, C., Puchades, M. J., et al. (2026) · Journal of Nephrology · doi:10.1093/joneph/aajag209
Heerspink, H. J. L., Arnott, C. G., Barratt, J., Campbell, K. N., Pecoits-Filho, R., Fukami, K., Halimi, J., Hou, F. F., Lam, C. S. P., Levin, A., et al. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag172 · Cited by 1
Self-citationPharmacoeconomic impact of empagliflozin in patients with chronic kidney disease
Kristeleva, D. A., Dyakov, I. N., & Zyryanov, S. K. (2026) · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology · doi:10.17749/2070-4909/farmakoekonomika.2026.399
Non-Albuminuric Diabetic Kidney Disease: Pathophysiology and Clinical Implications
Roh, E., & Kim, N. H. (2026) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2026.1009
Metadata
- Authors
- The EMPA-KIDNEY Collaborative Group, Herrington, W. G., Wanner, C., Green, J. B., Hauske, S. J., Judge, P., Mayne, K. J., Ng, S. Y. A., Sammons, E., Zhu, D., Staplin, N., Preiss, D., Stevens, W., Wallendszus, K., Dayanandan, R., Knott, C., Hill, M., Emberson, J., Brenner, S., Cejka, V., Cheung, A. K., Liu, Z., Li, J., Chen, P., Hooi, L., Liu, W., Kadowaki, T., Nangaku, M., Levin, A., Cherney, D., Pontremoli, R., Maggioni, A. P., Goto, S., Tomita, A., Deo, R., Tuttle, K., Eilbracht, J., Hantel, S., Hopley, M., Landray, M. J., Baigent, C., Haynes, R., Baigent, C., Landray, M. J., Wanner, C., Herrington, W. G., Haynes, R., Green, J. B., Hauske, S. J., Brueckmann, M., Hopley, M., Brenner, S., Cheung, A. K., Preiss, D., Liu, Z., Li, J., Hooi, L., Liu, W., Kadowaki, T., Nangaku, M., Levin, A., Cherney, D., Pontremoli, R., Maggioni, A. P., Staplin, N., Emberson, J., Hantel, S., Goto, S., Deo, R., Tuttle, K., Ng, S. Y. A., Lozano, F. J. R., Sammons, E., Zhu, D., Sandercock, P., Bilous, R., Herzog, C., Whelton, P., Wittes, J., Bennett, D., Burke, A., Brown, R., Dayanandan, R., Fletcher, L., Gosling, H., Harding, E., Haynes, R., Herrington, W. G., Judge, P., Knott, C., Lee, R., Murphy, K., Qiao, Y., Raff, R., Yu, H., Qiao, Y., Cejka, V., Fajardo-Moser, M., Lorimer, A., Lucci, D., Hepditch, A., Axler, A., Chen, P., Hao, D., Goh, C. B., Sivanandam, S., Hashimoto, A., Negoro, W., Tomita, A., & Tomoko, M.
- ORCID
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-03-03
- Volume
- 37
- Issue
- 7
- Pages
- 1317-1329
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- PMC
- PMC9217655
- OpenAlex
- W4213426937
- Cited by
- 110
- References
- 52
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 23 · 2023: 33 · 2022: 35
- FWCI
- 16.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nephrology Dialysis Transplantation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- empagliflozin, SGLT2 inhibitors, chronic kidney disease, kidney disease progression, cardiovascular mortality, diabetic nephropathy, glomerular disease, estimated glomerular filtration rate, urinary albumin-creatinine ratio, trial recruitment, trial design, EMPA-KIDNEY trial, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Glomerular Filtration Rate, Humans, Kidney, Male, Randomized Controlled Trials as Topic, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.